Literature DB >> 3741720

Altered pharmacokinetics of oral flecainide by cimetidine.

T B Tjandra-Maga, A van Hecken, P van Melle, R Verbesselt, P J de Schepper.   

Abstract

A potential kinetic interaction between cimetidine and flecainide has been studied in eight healthy males receiving flecainide (200 mg) orally on three occasions: before any treatment and on day 2 and day 7 of 8 days' cimetidine maintenance treatment at 1 g daily. Six days pretreatment with cimetidine induced the following changes in flecainide kinetic parameters: average tmax was prolonged from 1.8 h to 3.6 h and total AUC increased significantly from 4779 to 6131 ng ml-1 h. Plasma elimination half-life and renal clearance were not significantly altered. The fraction of flecainide dose excreted unchanged in urine rose significantly from 31 to 38%. The observed interaction can be explained by an increase in bioavailability or, more probably, by a decrease in biotransformation of flecainide in the presence of cimetidine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3741720      PMCID: PMC1401096     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

Review 1.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 2.  Metabolism of flecainide.

Authors:  G J Conard; R E Ober
Journal:  Am J Cardiol       Date:  1984-02-27       Impact factor: 2.778

3.  Quantitation of flecainide acetate, a new antiarrhythmic agent, in biological fluids by gas chromatography with electron-capture detection.

Authors:  J D Johnson; G L Carlson; J M Fox; A M Miller; S F Chang; G J Conrad
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

4.  Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs.

Authors:  A Somogyi; A McLean; B Heinzow
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  4 in total
  9 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

2.  The effects of cimetidine and ranitidine on the pharmacokinetics of cifenline.

Authors:  J W Massarella; T M Defeo; J Liguori; S Passe; K Aogaichi
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 4.  Safety of flecainide.

Authors:  Juan Tamargo; Alessandro Capucci; Philippe Mabo
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

5.  Altered flecainide disposition in healthy volunteers taking quinine.

Authors:  A Munafo; G Reymond-Michel; J Biollaz
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy.

Authors:  Markus Grube; Sabine Ameling; Michel Noutsias; Kathleen Köck; Ivonne Triebel; Karina Bonitz; Konrad Meissner; Gabriele Jedlitschky; Lars R Herda; Markus Reinthaler; Maria Rohde; Wolfgang Hoffmann; Uwe Kühl; Heinz-Peter Schultheiss; Uwe Völker; Stephan B Felix; Karin Klingel; Reinhard Kandolf; Heyo K Kroemer
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

Review 7.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

Review 8.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

9.  Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide.

Authors:  S Abel; D J Nichols; C J Brearley; M D Eve
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.